2 results
Approved WMORecruiting
The main objective of PD0053 is to provide POC for the efficacy of the ASYN misfolding inhibitor UCB0599 in reducing disease progression in study participants with early-stage PD, and to instruct later stage development. The ultimate goal is to…
Approved WMORecruiting
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on PFS and ORR in subjects with RAI-refractory DTC who have progressed after prior VEGFR-targeted therapy.